{"TopicDetails": {"type": 0, "ccm2Id": 31100161, "cftId": 0, "identifier": "IMI2-2018-15-08", "title": "AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic", "publicationDateLong": 1531872000000, "callIdentifier": "H2020-JTI-IMI2-2018-15-two-stage", "callTitle": "H2020-JTI-IMI2-2018-15-two-stage", "callccm2Id": 31100164, "allowPartnerSearch": true, "workProgrammepart": {"id": 267551, "ccm_id": 31095847, "wp_part": "H2020-JTI-IMI-2018", "wp_year": "H2020-JTI-IMI-2018", "wp_title": "H2020-JTI-IMI-2018", "wp_website": "http://www.imi.europa.eu/", "wp_document": "http://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp18-imi2_en.pdf"}, "frameworkProgramme": {"id": 31045243, "abbreviation": "H2020", "description": "Horizon 2020 Framework Programme"}, "programmeDivision": [{"id": 31047894, "abbreviation": "EU.3.1.", "description": "Health, demographic change and wellbeing"}, {"id": 31047893, "abbreviation": "EU.3.", "description": "Societal Challenges"}, {"id": 31062059, "abbreviation": "EU.3.1.7.", "description": "Innovative Medicines Initiative 2 (IMI2)"}, {"id": 31045244, "abbreviation": "EC", "description": "EC Treaty"}], "topicMGAs": [], "tags": ["Innovative Medicines Initiative", "AMR", "IMI2-2018-15-08", "Antimicrobial resistance", "IMI2", "AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic", "Joint Undertaking", "H2020-JTI-IMI2-2018-15-two-stage", "IMI2 JU"], "keywords": ["Antimicrobial resistance"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "IMI2-RIA Research and Innovation action", "typeOfMGA": []}], "plannedOpeningDate": "18 July 2018", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["24 October 2018", "15 May 2019"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3272690": [{"action": "IMI2-2018-15-03 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-02 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-01 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-08 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-07 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-04 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-05 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}, {"action": "IMI2-2018-15-06 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "18 July 2018", "deadlineModel": "two-stage", "deadlineDates": ["24 October 2018", "15 May 2019"], "budgetYearMap": {"2018": 386722862}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2018"]}, "description": "<SPAN class=\"topicdescriptionkind\">Specific Challenge</SPAN>:<p>There are significant scientific challenges to the discovery and development of new agents to treat and prevent AMR infections, including those caused by Gram-positive and Gram-negative bacteria, <em>Mycobacterium tuberculosis</em>, and non-tubercular mycobacteria (NTM). The AMR Accelerator will provide, under one operational structure, a wide-ranging series of projects that will address many of the scientific challenges in AMR.</p><p>TB is the leading cause of death from a single infectious agent worldwide. The lack of efficiency of current TB drugs is emphasised by the nearly 1.8 million annual deaths reported by World Health Organisation (WHO). Of these, 200 000 were confirmed cases of drug resistant TB, although real estimates could be much higher. As expressed by the United Nations (UN), a massive scale-up and a dynamic, global, multi-sectoral approach is needed if the global target of eradicating tuberculosis by 2030 is to be met. At present, there is a strong consensus both in private and public research sectors working on TB that having a large number of new drug candidates, which are ready to enter into clinical combination studies, is the most critical step to achieving this aspirational goal that will have a tremendous impact on global health.</p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The TB drug development Network (TBDDN), pillar B of the IMI2 AMR Accelerator programme, will function as a platform based on the principles of open innovation to advance discovery, preclinical and early clinical projects in the field of TB and MDR-TB. One of the objectives of the TBDDN is to become a worldwide reference for the development of novel candidates and regimens by sharing results generated by partners and peers from small and medium-sized enterprises (SMEs), public institutions and pharmaceutical companies</p><p>Specifically, the scope of this action is to: (1) coordinate, profile and progress the portfolio of anti-TB compounds existing within the industry consortium (EFPIA companies and Associated Partners) from the advanced lead stage through Phase 1 (candidates ready to enter into Ph-2 clinical studies); (2) identify preferred drug partners for preclinical combination studies that will facilitate the design of combination regimens consisting of new TB drugs with an indication for the treatment of any form, including MDR, of TB (pan-TB regimen); (3) create additional tools and technologies to progress anti-TB compounds, and to provide learnings derived from the analysis of shared anti-TB clinical trial data; (4) develop new alternative anti-tubercular drugs (host-defence or virulence approaches); (5) act as an interface with stakeholders in the TB field and explore synergies and collaboration with the action resulting from IMI2 JU Call 15, topic 7 and potential TB-focused actions from IMI2 JU Call 16 as well as other AMR initiatives.</p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p>The impact of the TBDDN will help attain the UN 2030 objective by: (1) providing new tools and understandings to progress TB science for the discovery of new preclinical candidates and novel combination regimens across the TB R&amp;D landscape; (2) contributing to the development of a vibrant TB research environment in the EU and strengthening the competitiveness and industrial leadership of Europe; (3) contributing to EU\u2019s ambition of being a \u2018best practice region\u2019 for addressing AMR; (4) enabling the progression of potential new treatment solutions for TB patients worldwide using a preferential pricing approach for low- and middle-income countries, with the intent to improve the quality of life and life expectation of TB patients; (5) strengthening interaction of TB R&amp;D stakeholders from across the EU and globally.</p>\n", "conditions": "<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">Please read carefully all provisions stated below before the preparation of your application.<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">The IMI2 JU 15th Call for proposals topics text as well as the Call Conditions are available </span></b><b><u><span style=\"font-size:9.0pt;font-family:&#10;&quot;Arial&quot;,sans-serif;mso-fareast-font-family:&quot;Times New Roman&quot;;color:blue;&#10;mso-fareast-language:EN-GB\"><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche18-15-imi2-ju_en.pdf\" target=\"_blank\">here</a></span></u></b><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">.&nbsp;&nbsp;</span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">The budget breakdown for this Call is given at the end of the Call topics text, in the </span></b><b><u><span style=\"font-size:9.0pt;font-family:&#10;&quot;Arial&quot;,sans-serif;mso-fareast-font-family:&quot;Times New Roman&quot;;color:blue;&#10;mso-fareast-language:EN-GB\"><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche18-15-imi2-ju_en.pdf\" target=\"_blank\">Call Conditions</a></span></u></b><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"> section, as well as the following information :&nbsp;</span></b></p>\r\n<p class=\"MsoNormal\" style=\"mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;&#10;line-height:normal\"><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>1.&nbsp;&nbsp; Eligible countries:</strong></span> described in article 10(2) of the <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/rules_participation/h2020-rules-participation_en.pdf\" target=\"_blank\">Rules for participation in  Horizon 2020</a> and in article 1 of the <a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0622\" target=\"_blank\">Commission Delegated Regulation related to IMI JU</a>.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>2.&nbsp;&nbsp; Eligibility and admissibility conditions:</strong></span> described in the <strong><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.6_en.pdf\" target=\"_blank\">IMI2 Manual for evaluation, submission and grant award</a>.</strong>  See also the <a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32014R0622\" target=\"_blank\">Commission Delegated Regulation related to IMI JU</a>.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Proposal page limits and layout:</strong></span> Please refer to Part B of the proposal template in the submission tool below.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>3.&nbsp;&nbsp; Evaluation: </strong></span><br />\r\nSubmission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the <strong><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju-v1.6_en.pdf\" target=\"_blank\">IMI2 Manual for submission, evaluation and grant award</a></strong>. See also the proposal templates for your specific action in section 5, below.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>4.&nbsp;&nbsp; Indicative time for evaluation and grant agreement: </strong></span><br />\r\nNotification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.<br />\r\nNotification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full proposals.</p>\r\n<p>Signature of grant agreements: maximum 3 months from the date of informing successful applicants.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>5.&nbsp;&nbsp; Proposal templates, evaluation forms and model grant agreements (MGA):</strong></span></p>\r\n<p><strong>IMI2 Research and Innovation Action (IMI2-RIA) </strong><strong>and Innovation Action (IMI2-IA):</strong></p>\r\n<p>Proposal templates are available after entering the submission tool<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/call_ptef/ef/h2020-call-ef-imi2-ria-ia-2016_en.pdf\" target=\"_blank\"><br />\r\nStandard evaluation form</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jtis/h2020-mga-imi_en.pdf\" target=\"_blank\">IMI2 Model Grant Agreement</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/legal/templ/h2020_tmpl-clinical-studies_2018-2020_en.pdf \" target=\"_blank\">Clinical trial template</a>&nbsp;&ndash; the Clinical Trial template is compulsory at stage 2 only !</p>\r\n<p>&nbsp;</p>\n<p><strong><span style=\"color: rgb(0, 51, 102);\">6.&nbsp;&nbsp; Open access must be granted to all scientific publications </span></strong>resulting from Horizon 2020 actions.</p>\r\n<p>Where relevant, proposals should also provide information on how the  participants will manage the research data generated and/or collected  during the project, such as details on what types of data the project  will generate, whether and how this data will be exploited or made  accessible for verification and re-use, and how it will be curated and  preserved.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Open access to research data</strong></span><br />\r\nThe Open Research Data Pilot has been extended to cover all Horizon 2020  topics for which the submission is opened on 26 July 2016 or later.  Projects funded under this topic will therefore by default provide open  access to the research data they generate, except if they decide to  opt-out under the conditions described in <a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2018-2020/annexes/h2020-wp1820-annex-l-openaccess_en.pdf\" target=\"_blank\">Annex L of the H2020 main Work Programme</a>. Projects can opt-out at any stage, that is both before and after the grant signature.</p>\r\n<p>Note that the evaluation phase proposals will not be evaluated more  favourably because they plan to open or share their data, and will not  be penalised for opting out.</p>\r\n<p>Open research data sharing applies to the data needed to validate the  results presented in scientific publications. Additionally, projects  can choose to make other data available open access and need to describe  their approach in a Data Management Plan.</p>\r\n<p>Projects need to create a Data Management Plan (DMP), except if they  opt-out of making their research data open access. A first version of  the DMP must be provided as an early deliverable within six months of  the project and should be updated during the project as appropriate. The  Commission already provides guidance documents, including a template  for DMPs. See the <a href=\"https://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/open-access-dissemination_en.htm\" target=\"_blank\">Online Manual</a>.</p>\r\n<p>Eligibility of costs: costs related to data management and data  sharing are eligible for reimbursement during the project duration.</p>\r\n<p>The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.&nbsp;</p>\n<p>Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.</p>\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>7. Additional documents:</strong></span></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-rel-prov-imi-ju_en.pdf\" target=\"_blank\">Summary of the most relevant provisions for participating in IMI2 actions</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/other/wp/jtis/h2020-wp18-imi2-amend-3_en.pdf\" target=\"_blank\">3rd Amended IMI2 Annual Work Plan 2018<br />\r\n</a><br />\r\n<a href=\"https://www.imi.europa.eu/sites/default/files/uploads/documents/apply-for-funding/call-documents/imi2/RegulatoryRequirementsGuide.pdf\" target=\"_blank\">IMI2 Regulators Guidance tool for researchers</a></p>\r\n<p><a href=\"http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:JOL_2014_174_R_0003\" target=\"_blank\">IMI JU derogation to H2020 Rules for Participation</a> &nbsp;<br />\r\n<br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/rules_participation/h2020-rules-participation_en.pdf\" target=\"_blank\">Horizon 2020 Rules for Participation&nbsp;</a></p>\r\n<p><a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/fp/h2020-eu-establact_en.pdf\" target=\"_blank\">Horizon 2020 Regulation of Establishment <br />\r\n</a><br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/h2020/legal_basis/sp/h2020-sp_en.pdf\" target=\"_blank\">Horizon 2020 Specific Programme</a></p>\r\n<p>&nbsp;</p>", "supportInfo": "<p><span style=\"color: rgb(0, 51, 102);\"><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/index_en.htm\" target=\"_blank\"><strong>H2020 Online Manual</strong></a> </span>is your guide on the procedures from proposal submission to managing your grant.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/portal/desktop/en/support/faq.html#c,faqs=categoryMachineName/t/pp_roles_and_rights/0/1/1/category&amp;categoryMachineName/t/p_registration/0/1/1/category&amp;categoryMachineName/t/work_programme_calls/0/1/1/category&amp;categoryMachineName/t/p_submission_eval/1/1/1/category&amp;categoryMachineName/t/ethics_research_integrity/0/1/1/category&amp;categoryMachineName/t/grants/0/1/1/category&amp;categoryMachineName/t/audit/0/1/1/category&amp;categoryMachineName/t/experts/0/1/1/category&amp;categoryMachineName/t/eu_research_policy/0/1/1/category&amp;programmeList/t/H2020/0/1/1/programme&amp;programmeList/t/3rd_health_programme/0/1/1/programme&amp;programmeList/t/asylum_migration_and_integration_fund/0/1/1/programme&amp;programmeList/t/consumer_programme/0/1/1/programme&amp;programmeList/t/COSME/0/1/1/programme&amp;programmeList/t/creative_europe_programme/0/1/1/programme&amp;programmeList/t/erasmus_programme/0/1/1/programme&amp;programmeList/t/FP7/0/1/1/programme&amp;programmeList/t/hercule_iii_programme/0/1/1/programme&amp;programmeList/t/internal_security_fund_borders/0/1/1/programme&amp;programmeList/t/internal_security_fund_police/0/1/1/programme&amp;programmeList/t/justice_programme/0/1/1/programme&amp;programmeList/t/pilot_projects_preparatory_actions/0/1/1/programme&amp;programmeList/t/promotion_of_agricultural_products/0/1/1/programme&amp;programmeList/t/research_fund_for_coal_and_steel/0/1/1/programme&amp;programmeList/t/rights_equality_and_citizenship_programme/0/1/1/programme&amp;programmeList/t/union_civil_protection_mechanism/0/1/1/programme&amp;programmeList/t/european_statistics/0/1/1/programme&amp;tagList/t/MSCA/0/1/1/tag&amp;tagList/t/ERC/0/1/1/tag\" target=\"_blank\"><strong><span style=\"color: rgb(0, 51, 102);\">Participant Portal FAQ</span></strong></a> &ndash; Submission of proposals.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/portal4/desktop/en/support/national_contact_points.html\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>National Contact Points (NCP)</strong></span></a> - contact your NCP for further assistance in your national language(s).</p>\r\n<p><a href=\"http://ec.europa.eu/research/index.cfm?lg=en&amp;pg=enquiries\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>Research Enquiry Service</strong></span></a> &ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong><a href=\"http://een.ec.europa.eu/\" target=\"_blank\">Enterprise Europe Network</a> </strong></span>&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.</p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/api/contact/index.html\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>IT Helpdesk</strong></span></a><strong> </strong>- contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.</p>\r\n<p><span style=\"color: rgb(0, 51, 102);\"><strong>Ethics</strong></span> &ndash; for compliance with ethical issues, see the <a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm\" target=\"_blank\">Online Manual</a> and <a href=\"http://ec.europa.eu/research/swafs/index.cfm?pg=policy&amp;lib=ethics\" target=\"_blank\">Science and Society Portal</a></p>\r\n<p><a href=\"http://www.iprhelpdesk.eu/\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>European IPR Helpdesk</strong></span></a> assists you on intellectual property issues</p>\r\n<p><a href=\"https://www.cencenelec.eu/research/Pages/default.aspx\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>CEN</strong></span><strong> <span style=\"color: rgb(0, 51, 102);\">and</span> </strong><span style=\"color: rgb(0, 51, 102);\"><strong>CENELEC</strong></span></a>, the <span style=\"color: rgb(0, 51, 102);\"><strong>European Standards Organisations</strong></span>, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at <span style=\"color: rgb(0, 0, 255);\">research@cencenelec.eu</span></p>\r\n<p><a href=\"http://ec.europa.eu/euraxess/pdf/brochure_rights/am509774CEE_EN_E4.pdf\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>The European Charter for Researchers and the Code of Conduct for their recruitment</strong></span></a></p>\r\n<p><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/grants/applying-for-funding/find-partners_en.htm\" target=\"_blank\"><span style=\"color: rgb(0, 51, 102);\"><strong>Partner Search Services</strong></span></a> help you find a partner organisation for your proposal.</p>\r\n<p><a href=\"https://www.imi.europa.eu/about-imi/governance/states-representatives-group\" target=\"_blank\"><strong>IMI2 States Representative Group (SRG)</strong></a><strong> &ndash; contact you SRG member for assistance.</strong></p>\r\n<p><a href=\"mailto:applicants@imi.europa.eu?subject=Info%20request%20about%20IMI2%20JU%20Call%2015%20Topic%20xx\" target=\"_blank\"><strong>IMI2 JU Applicants Helpdesk</strong></a><strong> &ndash; contact the IMI2 Programme Office</strong></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Sumission Service, please click on the submission-button next to the type of action that corresponds to your proposal. You will then be asked to confirm your choice of the type of action and topic, as these cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Participant Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [{"callId": 52392626123, "id": 165915003, "title": "IMI2 Call 15 stage 1 - Flash Call Info Report ", "sectionId": 52392626123, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 225756, "docPath": "https://ec.europa.eu/info/funding-tenders/opportunities/docs/cap/h2020/imi2-2018-15-08/1840130-imi2_call_15_-_flash_call_info_report_-_stage_1_en.pdf", "id": 1840130, "fileName": "IMI2 Call 15 - Flash Call Info report - stage 1_EN.pdf", "common": false, "crc32": 1619582921}]}, {"callId": 52392626123, "id": 165915004, "title": "IMI2 Call 15 stage 2 - Flash Call Info Report ", "sectionId": 52392626123, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 223919, "docPath": "https://ec.europa.eu/info/funding-tenders/opportunities/docs/cap/h2020/imi2-2018-15-08/1865115-imi2_call_15_-_flash_call_info_report_-_stage_2_en.pdf", "id": 1865115, "fileName": "IMI2 Call 15 - Flash Call Info report - stage 2_EN.pdf", "common": false, "crc32": 4002848585}]}], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Jul 16, 2019 4:28:44 PM", "lastChangeDate": "Jul 16, 2019 4:28:44 PM", "content": "<p>An overview of the evaluation results (<a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2018-15-02/1865115-imi2_call_15_-_flash_call_info_report_-_stage_2_en.pdf\" target=\"_blank\">flash call info &ndash; IMI2 Call 15 &ndash; second stage</a>) is now available under the call &lsquo;Additional documents&rsquo; tab</p>"}, {"approvalDate": "Jan 9, 2019 2:37:43 PM", "lastChangeDate": "Jan 9, 2019 2:37:43 PM", "content": "<p class=\"MsoNormal\">\r\n<p class=\"MsoNormal\">An overview of the evaluation results (<a href=\"http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2018-15-01/1840130-imi2_call_15_-_flash_call_info_report_-_stage_1_en.pdf\" target=\"_blank\">flash call info &ndash; IMI2 Call 15 &ndash; first stage</a>) is now available under the call &lsquo;Additional documents&rsquo; tab<o:p></o:p></p>\r\n</p>"}, {"approvalDate": "Oct 25, 2018 11:36:31 AM", "lastChangeDate": "Oct 25, 2018 11:36:31 AM", "content": "<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">Proposal numbers</span></b><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">Stage 1 submission deadline for the Call<b> IMI2-2018-15-two-stage </b>has closed on the <b>24 October 2018.</b><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">42 proposals have been submitted.<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">The breakdown per topic is:<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-01: &nbsp;&nbsp;2<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-02:&nbsp;15<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-03:&nbsp; &nbsp;3<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-04:&nbsp;&nbsp; 2<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:FR-BE;mso-fareast-language:EN-IE\">IMI2-2018-15-05: &nbsp;&nbsp;8<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">IMI2-2018-15-06:&nbsp;&nbsp; 6<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">IMI2-2018-15-07:&nbsp;&nbsp; 3<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-ansi-language:EN-IE;mso-fareast-language:EN-IE\">IMI2-2018-15-08:&nbsp;&nbsp; 3<o:p></o:p></span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size:12.0pt;font-family:&quot;Times New Roman&quot;,serif;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language:&#10;EN-IE;mso-fareast-language:EN-IE;mso-bidi-language:AR-SA\">Evaluation results for stage 1 are expected to be communicated in January 2019.</span></p>"}, {"approvalDate": "Jul 18, 2018 12:30:00 AM", "lastChangeDate": "Jul 18, 2018 12:30:00 AM", "content": "The submission session is now available for: IMI2-2018-15-01(IMI2-RIA), IMI2-2018-15-03(IMI2-RIA), IMI2-2018-15-02(IMI2-RIA), IMI2-2018-15-07(IMI2-RIA), IMI2-2018-15-08(IMI2-RIA), IMI2-2018-15-05(IMI2-RIA), IMI2-2018-15-04(IMI2-RIA), IMI2-2018-15-06(IMI2-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}